The increased focus of Chinese companies on innovative drugs led to the approval of 30 medicines discovered in China in 2023, accounting for 37% of new drugs approved in China overall. Here, with the aim of illuminating the evolution in pharmaceutical R&D in China in recent years, we overview the current pipeline of domestic innovative drug candidates and compare it with our previous analysis from 2021 (Nat. Rev. Drug Discov. 21, 553–554; 2022). For details of the dataset and analysis, see Supplementary Box 1.
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
206,07 € per year
only 17,17 € per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Acknowledgements
The authors gratefully acknowledge the Pharmcube team for their contribution to the work. This work was funded by National Natural Science Foundation of China (72374119) and Beijing Nova Program.
H.H. is an employee at Pharmcube. The other authors declare no competing interests.
CMLR's goal is to advance machine learning-related research across a wide range of disciplines. Beijing, China Center for Machine Learning Research (CMLR), Peking University
The Beijing Laser Accelerator Innovation Center at Peking University invites applications for Applied Physics faculty, including tenured positions. Beijing, China Peking University (PKU)
Dallas, Texas (US) The University of Texas Southwestern Medical Center (UT Southwestern Medical Center)
Northwell Health has formed a strategic partnership with the NCI-designated Cancer Center at Cold Spring Harbor Laboratory (CSHL). The institutions. Manhasset, New York Northwell
Dallas, Texas (US) The University of Texas Southwestern Medical Center (UT Southwestern Medical Center)